Back
ESC Professional Premium Access

Primary inflammatory disease in heart failure with preserved ejection fraction

Session: Cardiac amyloidosis, sarcoidosis, and inflammation
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Speaker: Doctor A. Tada (Rochester, US)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Atsushi Tada

Mayo Clinic, Rochester (United States of America)
0 follower

8 more presentations in this session

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Speaker: Doctor J. Vogel (Essen, DE)

Access
Abstract
Slides
Video
Like
Thumbnail

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Speaker: Mr V. Ribeiro (Teresina, BR)

Access
Abstract
Slides
Video
Like
Thumbnail

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

Speaker: Mr S. Decotto (Buenos Aires, AR)

Access
Abstract
Slides
Video
Like
Thumbnail

Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

Speaker: Doctor J. Vogel (Essen, DE)

Access
Abstract
Slides
Like
Thumbnail

Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

Speaker: Ms A. Senda (Kobe, JP)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Cardiac amyloidosis, sarcoidosis, and inflammation

Speakers: Doctor A. Tada, Doctor J. Vogel, Mr V. Ribeiro, Mr S. Decotto, Doctor J. Vogel...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources